Oxular is a pioneering biotechnology company focused on developing novel drug-device combination treatments for sight-threatening retinal diseases. Operating in the ophthalmology market, Oxular primarily serves patients suffering from severe retinal disorders, including age-related macular degeneration and diabetic retinopathy. The company's business model revolves around the research, development, and commercialization of its proprietary treatments, which are designed to be administered via the suprachoroidal space in the eye, offering targeted and sustained drug delivery. Oxular generates revenue through clinical trials, partnerships, and eventual product sales upon regulatory approval. The company is currently advancing its pipeline with key projects like the OXEYE Phase 2 Clinical Trial and has recently received IND clearance for OXU 001. Led by CEO Mark Gaffney, who brings 20 years of biotech life sciences experience, Oxular aims to transform the treatment landscape for retinal diseases, thereby improving patients' vision and quality of life.

Keywords: retinal diseases, drug-device combination, suprachoroidal delivery, ophthalmology, clinical trials, biotech, vision improvement, age-related macular degeneration, diabetic retinopathy, regulatory approval.